Secondary resistance to immunotherapy associated with [beta]-catenin pathway activation or PTEN loss in metastatic melanoma

Background While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of patients who initially respond subsequently develop secondary resistance to therapy...

Full description

Saved in:
Bibliographic Details
Published inJournal for immunotherapy of cancer Vol. 7; no. 1
Main Authors Trujillo, Jonathan A, Luke, Jason J, Zha, Yuanyuan, Segal, Jeremy P, Ritterhouse, Lauren L, Spranger, Stefani, Matijevich, Karen, Gajewski, Thomas F
Format Journal Article
LanguageEnglish
Published BioMed Central Ltd 08.11.2019
Subjects
Analysis
Antibodies
Cancer
Cancer metastasis
Cancer treatment
Criminal investigation
EDTA
Genetic research
Health aspects
Immunotherapy
Peptides
Recurrence (Disease)
Scientific equipment industry
T cells
Transcription (Genetics)
Tumors
Vaccines
United States
Online AccessGet full text

Cover

More Information
Summary:Background While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of patients who initially respond subsequently develop secondary resistance to therapy. Tumor-intrinsic mechanisms of acquired immunotherapy resistance are incompletely understood. Methods Baseline and treatment-resistant tumors underwent molecular analysis via transcriptional profiling or genomic sequencing for oncogenic alterations and histologic analysis for T cell infiltration to investigate mechanisms contributing to T cell exclusion and acquired resistance to immunotherapy. Results We describe two patients with metastatic melanoma who initially showed a durable partial response to either a melanoma-peptide/interleukin-12 vaccine or combined anti-CTLA-4 + anti-PD-1 therapy, but subsequently developed new treatment-resistant metastases. In the first case, the recurrent tumor showed new robust tumor expression of [beta]-catenin, whereas in the second case genomic sequencing revealed acquired PTEN loss. Both cases were associated with loss of T cell infiltration, and both pathways have been mechanistically linked to immune resistance preclinically. Conclusion Our results suggest that secondary resistance to immunotherapies can arise upon selection for new oncogenic variants that mediate T cell exclusion. To identify the spectrum of underlying mechanisms of therapeutic resistance, similar evaluation for the emergence of tumor-intrinsic alterations in resistant lesions should be done prospectively at the time of relapse in a range of additional patients developing secondary resistance. Keywords: Immune checkpoint blockade, Peptide vaccine, Secondary resistance, PTEN-loss, [beta]-Catenin activation, Immune exclusion, Next-generation sequencing
ISSN:2051-1426
2051-1426
DOI:10.1186/s40425-019-0780-0